Lexeo Therapeutics receives FDA Fast Track designation for LX2006 gene therapy for FA cardiomyopathy

Lexeo Therapeutics, Inc.

FDA granted Fast Track designation for LX2006 (AAVrh.10hFXN gene therapy) for Friedreich's ataxia cardiomyopathy.
LX2006 aims to deliver functional frataxin gene to restore mitochondrial function in myocardial cells.
Phase 1/2 SUNRISE-FA trial ongoing to evaluate safety, tolerability, and preliminary efficacy in FA cardiomyopathy.
LX2006 previously received Rare Pediatric Disease and Orphan Drug designations; Fast Track may accelerate development.
FA cardiomyopathy is the leading cause of death among FA patients, with no approved treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.